SEATTLE--Immunex has obtained an experimentation license for a molecule identified by Digital Gene Technology's Total Gene Expression Analysis (TOGA) technology as applied to Immunex's advanced gastrointestinal tract inflammation models in a collaboration begun in December 1997. The molecule will now be studied by Immunex researchers in their ongoing investigation of the molecular basis of gut inflammation pathologies, Immunex stated.
Other molecules from the first-round TOGA results, including both previously known genes new to the inflammation model and a number of never-before-encountered genes, are expected to be added to Immunex's experimentation license this summer.
TOGA is Digital's patented method of identifying and determining the concentration of nearly all of the genes active in a sample cell or tissue. The method, developed at the Scripps Research Institute in the laboratory of Gregor Sutcliffe, a company founder and chairman of Digital's scientific advisory board, provides an inventory of gene activity in a sample and constitutes a major new approach to defining the function of the vast array of genes comprising any genome.
American Home Products owns a majority interest in Immunex.